UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening

Abstract

BackgroundLung cancer screening using low-dose CT (LDCT) was shown to reduce lung cancer mortality by 20% in the National Lung Screening Trial.MethodsThe pilot UK Lung Cancer Screening (UKLS) is a randomised controlled trial of LDCT screening for lung cancer versus usual care. A population-based questionnaire was used to identify high-risk individuals. CT screen-detected nodules were managed by a pre-specified protocol. Cost effectiveness was modelled with reference to the National Lung Cancer Screening Trial mortality reduction.Results247 354 individuals aged 50–75 years were approached; 30.7% expressed an interest, 8729 (11.5%) were eligible and 4055 were randomised, 2028 into the CT arm (1994 underwent a CT). Forty-two participants (2.1%) had confirmed lung cancer, 34 (1.7%) at baseline and 8 (0.4%) at the 12-month scan. 28/42 (66.7%) had stage I disease, 36/42 (85.7%) had stage I or II disease. 35/42 (83.3%) had surgical resection. 536 subjects had nodules greater than 50 mm3 or 5 mm diameter and 41/536 were found to have lung cancer. One further cancer was detected by follow-up of nodules between 15 and 50 mm3 at 12 months. The baseline estimate for the incremental cost-effectiveness ratio of once-only CT screening, under the UKLS protocol, was £8466 per quality adjusted life year gained (CI £5542 to £12 569).ConclusionsThe UKLS pilot trial demonstrated that it is possible to detect lung cancer at an early stage and deliver potentially curative treatment in over 80% of cases. Health economic analysis suggests that the intervention would be cost effective—this needs to be confirmed using data on observed lung cancer mortality reduction.Trial registrationISRCTN 78513845.

Bronchialkarzinomscreening – Risikostratifizierung

“…Tab. 2) eine höhere Sensitivität (83,0 vs. 71,0 %) sowie einen höheren positiven prädiktiven Wert (4,0 vs. 3,4 %) ohne eine Abnahme der Spezifität (62,9 vs. 62,7 %) …”

Management of pulmonary nodules according to the 2015 British Thoracic Society guidelines. Key messages for clinical practice

“…78 Surgical series may not reflect the contemporary world of pulmonary nodules but the recently published UK lung cancer screening study, which adopted a similar protocol to that of the BTS guideline, showed a benign resection rate of only 10%. 79 No studies have specifically addressed the issue of what constitutes an optimal or acceptable benign resection rate. Factors that influence the threshold for surgical resection include the risk of morbidity and mortality for excision (particularly if the nodule turns out to be benign) compared to the possibility of stage progression during a period of radiological surveillance.…”

Screening for lung cancer – are we nearly there yet?

“…When the threshold is set at 5mm, as recommended by the British Thoracic Society (BTS) Guidelines, 7 this figure is estimated to be around 25%. 8 Despite this disadvantage, LDCT screening is considered to be cost-effective, at an estimated cost per quality-adjusted life year gained of around £9000. 8 At this figure, it would be likely to be accepted as a costeffective intervention by NICE.…”